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ABSTRACT 
Opiates have been used historically for the treatment of depression. Renewed 
interest in the use of opiates as antidepressants has focussed on the development of 
kappa opioid receptor (-receptor) antagonists. Buprenorphine acts as a partial -
opioid receptor agonist and a -receptor antagonist. By combining buprenorphine 
with the opioid antagonist naltrexone, the activation of -opioid receptors would be 
reduced and the -antagonist properties enhanced. We have established that a 
combination dose of buprenorphine (1mg/kg) with naltrexone (1mg/kg) functions as a 
short-acting -antagonist in the mouse tail withdrawal test. Furthermore, this dose 
combination is neither rewarding nor aversive in the conditioned place preference 
paradigm and is without significant locomotor effects. We have shown for the first 
time that systemic co-administration of buprenorphine (1mg/kg) with naltrexone 
(1mg/kg) in CD-1 mice produced significant antidepressant-like responses in 
behaviours in both the forced swim test and novelty induced hypophagia task. 
Behaviours in the elevated plus maze and light dark box were not significantly 
altered by treatment with buprenorphine alone, or in combination with naltrexone. 
We propose that the combination of buprenorphine with naltrexone represents a 
novel, and potentially a readily translatable approach, to the treatment of depression.  
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Introduction 
Opioid receptors are increasingly recognized to play a role in the regulation of 
mood and emotional behaviours (Lutz and Kieffer, 2013). Among the opioid receptors, 
kappa opioid receptors (-receptor) have recently been a focus for antidepressant and 
anxiolytic drug development (Carroll and Carlezon, 2013; Van’t Veer and Carlezon, 
2013). Dynorphins are endogenous neuropeptides that activate -receptors. Both 
dynorphins and -receptors are highly expressed in brain regions that mediate stress 
responses, cognitive and reward behaviours such as the amygdala, hypothalamus, 
locus coeruleus, hippocampus, ventral tegmental area and nucleus accumbens in 
human and rodent brains (Kitchen et al., 1997; Mansour et al., 1994). Dynorphin, 
released during stress exposure, or administration of -agonists induces 
prodepressive-like behaviour in rodents including increased immobility in the forced 
swim test (Carlezon et al., 2006; McLaughlin et al., 2003; Shirayama et al., 2004). In 
contrast, -receptor gene deletion or prodynorphin gene disruption has the ability to 
block stress induced prodepressive-like effects (McLaughlin et al., 2003; Wittmann et 
al., 2009). It has also been demonstrated that selective high affinity -receptor 
antagonists, such as norbinaltorphimine (norBNI), effectively reduce stress-induced 
prodepressive-like behaviours and have antidepressant-like and anxiolytic-like effects 
in rodents (Knoll et al., 2007; Mague et al., 2003; McLaughlin et al., 2003). Taken 
together these data suggest that -receptor antagonists may be effective in the 
treatment of comorbid depression and anxiety.  
 
The existing high affinity selective -antagonists, such as norBNI and  5'-
guanidinonaltrindole, have two distinct pharmacological properties; slow onset of 
antagonist activity and very long lasting effects in vivo (Beguin and Cohen, 2009; 
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Carroll and Carlezon, 2013). For example, one injection of norBNI has peak -
antagonist effects starting at about 24 h post-administration, continuing at high levels 
for 7–10 days and returning to control levels after 3–4 weeks or persisting for months 
(Endoh et al., 1992; Horan et al., 1992). This limits in vivo behavioural testing and 
potentially clinical trials if the blockade of -receptors may not be easily reversed. A 
variety of mechanisms may account for the unusual long duration of action of selective 
-antagonists including high lipophilicity leading to slow clearance from the brain, 
production of metabolites that are active at the receptors, resistance to metabolism 
which increases bioavailability or ligand-directed signalling producing a c-Jun N 
terminal kinase (JNK) mediated inactivation of the -receptor (Beguin and Cohen, 
2009; Bruchas and Chavkin, 2010).To overcome this issue, a number of selective 
shorter acting -receptor antagonists have recently been synthesised and 
characterised but have not yet reached the clinic (Casal-Dominguez et al., 2014; Eans 
et al., 2013; Peters et al., 2011; Ross et al., 2012; Verhoest et al., 2011). 
 
We have explored an alternative approach, using two drugs that are already licensed 
for other therapeutic indications. Buprenorphine is a semi-synthetic opioid with a 
unique complex pharmacology. Buprenorphine acts as a partial -receptor agonist 
and a -receptor antagonist with additional nociception/orphanin FQ receptor (NOP-
receptor, also known as ORL1) partial agonist activity (Huang et al., 2001; Lutfy and 
Cowan, 2004). Clinically, buprenorphine is used as a potent analgesic and as an 
alternative to methadone in the treatment of opioid addiction (Maremmani and Gerra, 
2010). In addition, buprenorphine has been shown to be effective in a small cohort of 
treatment-resistant depressed patients with clinical improvement evident within 1 
week of treatment (Bodkin et al., 1995). A more recent study, in a small cohort of 
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older treatment-resistant depressed adults, also suggests clinically significant 
improvements within 3 weeks of treatment (Karp et al., 2014).  Recently, 
buprenorphine has also been shown to have antidepressant- and anxiolytic-like 
activity in mice (Falcon et al., 2014). However, treatment with -agonists carries a 
risk of abuse liability and dependence. Naltrexone, is a relatively non-selective opioid 
receptor antagonist, with a higher affinity for - than -opioid receptors. In the UK it is 
licensed as an abstinence promoter for the treatment of alcohol addiction (Rosner et 
al., 2010). Combining naltrexone with buprenorphine could reduce the potential 
abuse liability of buprenorphine activating -receptors, while enhancing -receptor 
antagonist actions. Buprenorphine-naltrexone has proved safe and effective in 
treating drug dependence as it improves the dysphoria associated with drug 
withdrawal (Gerra et al., 2006). Also, it has recently been reported that a 
combination of buprenorphine with a -receptor antagonist samidorphan has 
antidepressant effects in major depressive disorder patients (Ehrich et al., 2015). 
Taken together these data suggest that buprenorphine in combination with 
naltrexone may have clinical utility as an antidepressant.  
  
The aim of this study was to identify doses of buprenorphine and naltrexone 
that when co-administered in mice, produces a functional, short-acting -antagonist. 
Subsequently, we have tested the dose combination to ensure that it is not sedating, 
nor rewarding, nor aversive. Finally, we have evaluated whether combination 
treatment with buprenorphine and naltrexone has antidepressant- and anxolytic-like 
potential in mice. 
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Methods and Materials 
Drugs 
Diazepam and U50,488 were purchased from Sigma (Dorset, UK). Fluoxetine and 
naltrexone were supplied by Abcam Biochemicals (Cambridge, UK).  Clocinnamox 
(CCAM) and norBNI were obtained from Tocris Bioscience (Bristol, UK). 
Buprenorphine was purchased from MacFarlan Smith (Edinburgh, UK). For in vivo 
experiments, all drugs were dissolved in 0.9% w/v saline (Hameln Pharmaceuticals, 
Gloucester, UK) and injected via the intraperitoneal route at a volume of 10ml/kg, 
except for CCAM which was injected at a volume of 20ml/kg.  
 
Animals 
Adult (8–10 weeks, 25–43 g) male CD-1 mice, bred in-house at the University of Bath 
for more than 10 years (originally from Charles River Crl:CD1(ICR)), were housed in 
groups of 4 to 5. In the homecages (30 x 16 x 14 cm), mice were provided with wood 
shavings and nesting material with ad libitum access to food and water. Mice were 
maintained on a 12:12 hours light–dark cycle (lights on 07:00 h; lights off 19:00 h) at 
20 ± 2°C. All experiments were performed in accordance with the UK Home Office 
guidelines and the Animals (Scientific Procedures) Act 1986. For all behavioural tasks 
animals were habituated to the behavioural room for one hour prior to the experiment 
beginning. Separate groups of animals, n=5-10 per treatment group, were used for 
each behavioural task. All behavioural experiments were performed between 9:00-
16:00 h and mice were acclimatized to the behavioural room for 1h prior to starting. 
 
Warm water tail-withdrawal test 
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The mice were scruffed and held in a vertical position, and the distal third of the tail 
lowered into a water bath maintained at 52°C. The latency for the mouse to withdraw 
the tail was recorded. A 15-second cut-off was imposed to avoid tissue damage. 
Antinociception was calculated as percentage maximum possible effect (%MPE) = 
(test latency–control latency)/(15 s–control latency) ×100. To determine the time 
course of the antinociceptive effects of buprenorphine (1 mg/kg) and the -agonist 
U50,488 (10 mg/kg), baseline latencies were determined 30 minute before injecting 
these drugs at time zero. To determine effective  and -antagonist doses (Figure 1 
A,B,C,D), naltrexone (0.3, 1 and 3 mg/kg) was injected 10 minutes prior to 
buprenorphine or U50,488 administration. Tail-withdrawal responses were measured 
at 30, 60, 120, 240 minute and 24 hours post-injection.  
 
To examine the duration of the -antagonist actions (Figure 1E), tail-withdrawal 
latency was measured at 1, 8, 24 and 48 h post-administration of antagonist, 
naltrexone (1 mg/kg) alone, or in combination with buprenorphine (1 mg/kg). In these 
experiments, naltrexone or saline was injected 10 mins before time zero. 
Buprenorphine or saline was injected at time zero. U50,488 or  saline was injected 30 
minute before taking a measurement to assess the extent of receptor blockade. In 
experiments with the irreversible, selective -antagonist CCAM (Broadbear et al., 
2000), CCAM was administered 24 h before treatment with buprenorphine/naltrexone 
(1 mg/kg) combination. To counteract any possible confounding effects of injection 
induced stress, in all experiments, animals received 0.9% w/v saline injections so that 
the total number of injections an individual mouse received, whether in control or in 
drug treated groups, was equivalent.  
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Conditioned place preference (CPP) 
Place preference conditioning was conducted in a CPP chamber with an auto 
monitoring system (Ethovision XT version 8.0). The apparatus (UGO Basile) 
consisted of a box with two compartments (16 x 15 cm / compartment) joined by a 
removable partition that allowed mice to freely explore or be restricted to a particular 
compartment. The two compartments differed in appearance and texture; one 
compartment had black walls and a grey floor with round 2mm holes whilst the other 
compartment had walls with vertical black and white stripes and a grey floor with 4 x 
4 mm square holes. Experiments were performed under dim light (approximately 15 
lux). During all test sessions, the time each mouse spent in each compartment was 
recorded using tracking software.  
 
Mice were randomly assigned to treatment groups and the pairing was 
counterbalanced (i.e. within each treatment group equal numbers of mice were 
always drug-paired to each compartment type). On days 1 and 2 mice were 
habituated to the entire chamber for 15 min (one session /day). On days 3-8 mice 
were conditioned (30 min) to one of the two compartments and daily sessions 
alternated between drug treatment and saline (in all treatment groups mice received 
both drug and saline). Three drug treatment groups (n=8 per group) were used and 
mice received buprenorphine (1mg/kg) administered 10 min after 0.9 % saline or 
naltrexone (1 mg/kg) or naltrexone (3 mg/kg). After buprenorphine injection the mice 
were transferred directly to the place preference box and at the end mice were 
returned to their home cage. Chamber floors and trays were removed and cleaned 
with ethanol 70 % and left for 5 minutes for ethanol to evaporate before the next trial. 
On day 9, mice were not injected with saline or drugs. In a free-to-explore test, 
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lasting 15 minutes, mice had free access to both compartments and their preference 
was determined by recording the time spent in the drug-paired chamber.  
 
Locomotor activity   
Locomotor activity was assessed in an open-field test . Testing was performed to 
establish the potential sedative effects of buprenorphine (1mg/kg) alone or in 
combination with naltrexone (0.3, 1 mg, and 3 mg/kg). Naltrexone was injected 10 
minute before buprenorphine. One hour post-administration, mice were placed singly 
in an open field (72 x 72 cm) for 10 minute under low light conditions (30 lux). Total 
activity was recorded by photobeam breaks using Motor Monitor software (Campden 
Instruments). 
 
Forced swim test 
Mice were individually placed inside a glass beaker (height 44 cm x diameter 22 cm) 
filled with water at a depth of 30 cm, at 25±2°C and behaviour recorded (Sony DCR-
SR52)  for 6 min (Casal-Dominguez et al., 2013). Mice were removed, dried and 
returned to their home cages. Mice were scored, blind for treatment, for three 
measures: swimming, immobility, climbing and the time spent engaged in these 
behaviours in the last 4 minutes of the test reported. Drug treatments were saline-
injected controls, buprenorphine (1mg/kg) alone, naltrexone (1mg/kg) alone, 
buprenorphine/naltrexone (1mg/kg) combination and the selective serotonin reuptake 
inhibitor (SSRI) fluoxetine (20 mg/kg). All drugs were administered 1 hour prior to 
testing (naltrexone 10 min before buprenorphine).  
 
Novelty-induced hypophagia  
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Mice were individually housed for 3 days before training began. Training consisted of 
3 consecutive days in which mice received concentrated milk (1:3; sweetened 
condensed milk: water) for 30 minute in their home cage and lighting levels were set 
to 20 lux (Dulawa and Hen, 2005). On day 4 mice underwent home cage testing. On 
day 5, novel cage testing was conducted by placing the mouse in a clean cage of the 
same dimensions as their home cage, but with no bedding or shavings and under 
bright lighting (300 lux, Fig 5A; 500 lux Fig 5B). The latency to drink was recorded 
during a 30-min test period in both the home and novel cage environments. In the first 
experiment (Figure 5A), mice received buprenorphine and naltrexone alone, or 
combined, or the SSRI fluoxetine (20 mg/kg) 1 h prior to testing (naltrexone 10 min 
before buprenorphine). Mice were also administered the -antagonist norBNI 
(10mg/kg; 24-48 h prior to testing, after training on day 3). In the second experiment 
(Figure 5B), the lighting was increased to make the novel cage more aversive and the 
ability of the irreversible -antagonist CCAM (3 mg/kg) to block the effects of 
buprenorphine and naltrexone was investigated by administration after training on day 
3. 
 
Elevated plus maze (EPM)   
Mice were placed in the centre of an EPM (EPM2000 Mouse Plus Maze, Campden 
Instruments) facing an open arm and behaviour was recorded for 5 min (Casal-
Dominguez et al., 2013). The time spent in, and entries into, the open and closed 
arms, and total ambulation were recorded via infrared photobeams and analyzed with 
Motor Monitor™ software (Campden Instruments). Illumination was 150 lux in the 
open arms and <1 lux in the closed arms. Mice (n=10/group) were treated with saline, 
buprenorphine (1 mg/kg) alone, naltrexone (1mg/kg) alone, buprenorphine/naltrexone 
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(1mg/kg) combination and diazepam (2mg /kg), a positive control, 1h prior to testing 
(naltrexone 10 min before buprenorphine).   
 
Light Dark Box (LDB) 
Mice were placed at the centre of the lit compartment (400 lux), facing the dark 
compartment and allowed free access between compartments for 10 min (Openfield 
SmartFrame, Campden Instruments) (Casal-Dominguez et al., 2013). The time spent 
in, and number of entries into, the lit compartment, and the distance travelled in the 
LDB were recorded via beam-breaks using Motor Monitor™ software (Campden 
Instruments). Mice (n=10/group) were treated with saline, buprenorphine (1 mg/kg) 
alone, naltrexone (1mg/kg) alone, buprenorphine/naltrexone (1mg/kg) combination 
and diazepam (2mg /kg) 1h prior to testing (naltrexone 10 min before buprenorphine).   
 
Statistical analysis 
All behavioural scoring was performed blind to treatment and data were analyzed 
using two-way repeated measures mixed model analysis or single measures one-way 
ANOVA followed by Unadjusted Least Significant Difference (ULSD) post hoc test 
(Invivostat 2.3). Only planned pairwise tests were carried out and p values adjusted 
for multiple comparisons with Benjamin-Hochberg correction. Values are reported as 
mean ± standard error of the mean (SEM) for each treatment group. 
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Results 
Establishing a combination dose of buprenorphine/naltrexone that is a 
functional kappa opioid receptor antagonist  
We used CD-1 mice for these studies as we have previously shown that this 
strain responds to the anxiolytic and antidepressant effects of a range of k-antagonist 
compounds (Casal-Dominguez et al., 2013). We first established doses of 
buprenorphine that would provide robust antinociception via activation of -opioid 
receptors in the warm water tail withdrawal assay. The antinociceptive activity of 
buprenorphine has been reported to have an inverted U-shaped dose response curve, 
with reduced antinociception at high doses (Lutfy and Cowan, 2004). Our data 
demonstrated that in CD1 mice 1 mg/kg buprenorphine produced a significant 
antinociceptive effect that was not enhanced at 3mg/kg and not evident at 0.3 mg/kg 
(Supplementary Figure 1). Furthermore, over this dose range, buprenorphine was 
without significant effects on locomotor activity (Supplementary Figure 2). 
We next established doses of naltrexone, a relatively non-selective opioid 
receptor antagonist (Giordano et al., 1990), that would block the partial µ-receptor 
agonist activity of buprenorphine using the warm water tail-withdrawal test (Figure 
1A,B, n=5 per group). Two-way repeated measures mixed model analysis revealed a 
significant interaction of Treatment * Time (F (24,120) = 2.46, p< 0.001). Buprenorphine 
(1mg/kg) produced a significant antinociceptive effect that peaked at 60 min post-
administration (p<0.001, compared to saline injected controls, figure 1B) returning to 
baseline after 240 min. Pre-treatment with naltrexone 1mg and 3mg/kg, but not 
0.3mg/kg, significantly blocked the buprenorphine-induced antinociception at 30 min 
(p< 0.01) and 60 min (p< 0.001). To determine the -antagonist properties of 
naltrexone, the -agonist U50,488 (10mg/kg) was used (Figure 1C,D, n=5 per group). 
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In this experiment there was a significant Treatment * Time interaction (F (24,114) =2.12, 
p< 0.004). U50,488 produced a significant antinociceptive effect 30 min post-
administration (p< 0.01)  that persisted for more than 240 min (p< 0.05 compared to 
saline controls).  Pretreatment with naltrexone 1mg and 3mg/kg, but not 0.3 mg/kg, 
significantly blocked the U50, 488-induced antinociception (all p’s < 0.01 compared to 
U50,488 alone).  
 
To determine whether naltrexone alone or buprenorphine/naltrexone 
combination has long acting -antagonist effects, their ability to block U50,488-
induced antinociception was tested at 1, 8, 24 and 48 h post-administration of 
antagonist (Figure 1E, n=5 per group). Two-way repeated measures mixed model 
analysis revealed that there was a significant interaction of Treatment * Time (F (12,64) 
=12.25, p<0.001). At 1 hour post-administration U50,488 produced a pronounced  
antinociceptive effect that was significantly reduced by naltrexone alone, or in 
combination with buprenorphine, 1 h post-administration (all p’s<0.001, compared to 
U50,488 alone). The -receptor blockade by naltrexone and by combination 
buprenorphine/naltrexone was not evident at 24 and 48h post-administration of 
antagonist (Figure 1E). At 8h post-administration of naltrexone, its ability to block 
U50,488 induced antinociception was reduced, compared to 1h.  Interestingly, at 8 hr 
post administration of buprenorphine/naltrexone, U50,488 induced an apparently 
potentiated antinociceptive effect (p<0.05 compared to U50,488 alone). In a separate 
experiment, the irreversible µ-antagonist CCAM (3mg/kg), administered 24h before 
this tail withdrawal assay was repeated, blocked this apparent potentiation of U50,488 
effects by buprenorphine/naltrexone at 8h, suggesting that it is a result of µ-receptor 
activation by buprenorphine or its metabolites (Figure 1F). Overall, these data show 
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that at 1 and 3mg/kg, naltrexone is an effective  and -antagonist, with -antagonist 
effects that are evident at 1 h post administration, reversing at 8h and completely 
reversed at 24 h. The combination of buprenorphine (1mg/kg) with naltrexone (1 
mg/kg) also produces a functional -antagonist with a rapid onset and a duration of 
action < 24 h. 
 
Effects of buprenorphine and naltrexone on locomotor activity 
To assess the locomotor effects of the ligands used in this study, behaviour in the 
open-field test was investigated (Figure 2). Buprenorphine alone (1 mg/kg) or in 
combination with naltrexone (0.3, 1, and 3 mg/kg), had no significant effects on total 
locomotion compared to saline treated controls (F (4,20) =0.62, p=0.657). Naltrexone 
(1mg/kg) alone had no significant locomotor effects (see Supplementary Figure 2). 
 
Establishing the rewarding properties of combination buprenorphine/ 
naltrexone in conditioned place preference (CPP) task  
 Mice receiving 1 mg/kg buprenorphine exhibited significant conditioned place 
preference, evident as a significantly increased time spent in the drug-paired 
compartment of the CPP chamber, compared to pre-conditioning (Figure 3) (pre-
conditioning: 451.6 ± 25.2s, post-conditioning: 587.1 ± 73.0s; n=8, p=0.05). However, 
co-administration of 1 and 3 mg/kg naltrexone completely blocked the conditioned 
place preference elicited by buprenorphine. While not significant, there was a trend for 
3mg/kg naltrexone to increase the time spent in the saline-paired compartment 
compared with preconditioning, suggesting that naltrexone at this dose may be 
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eliciting an aversive response. Therefore, in subsequent behavioural experiments, the 
combination of 1mg/kg buprenorphine and 1mg/kg naltrexone was used. 
 
Effects of combination buprenorphine/naltrexone on depression- and anxiety-
related behaviours 
 The effects of buprenorphine (1mg/kg) and naltrexone (1 mg/kg), alone or in 
combination, were compared with the SSRI fluoxetine (20mg/kg) in the forced swim 
test (Figure 4A, n=10 per group).  One-way ANOVA revealed a significant effect of 
Treatment on the time spent swimming (F (4, 45) =6.88, p< 0.001) and immobile (F (4, 45) 
= 6.97, p< 0.001). Post hoc comparisons to saline treated controls revealed that all 
drug treated groups increased the time spent swimming and decreased the time spent 
immobile during the last 4 minute of the test (all p’s < 0.001). Interestingly, immobility 
times for buprenorphine (1mg/kg) and naltrexone (1mg/kg) administered alone were 
not significantly different from the combination treatment.  
We further investigated whether the antidepressant-like effects of 
buprenorphine in the forced swim test were related to its partial -agonist activity 
(Figure 4B). The irreversible -antagonist CCAM (3mg/kg) was administered 24 h 
before buprenorphine or saline were injected and activity assessed 1 h later in the 
FST. One-way ANOVA revealed a significant effect of Treatment on the time spent 
swimming (F (4, 40) =8.84, p< 0.001) and immobile (F (4,40) = 7.77, p< 0.001). 
Buprenorphine alone, or in combination with CCAM, produced a significant increase 
in swimming, and a decrease in immobility, compared with saline (p< 0.01). CCAM 
alone produced no significant effects on behaviour in the forced swim test. These data 
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suggest that the antidepressant-like effects of buprenorphine alone were not mediated 
by effects at the -opioid receptor. 
  
 
 Behaviour of mice administered buprenorphine (1mg/kg) and naltrexone (1 
mg/kg), alone or in combination, were compared with the SSRI fluoxetine (20mg/kg) 
and the -antagonist norBNI (10mg/kg) in the novelty-induced hypophagia task (Figure 
5A, n= 10 per group). Two-way repeated measures mixed model analysis of the 
latency to drink times revealed significant main effects of Treatment (F (5, 54) =11.64, 
p<0.001) and a significant Treatment * Environment interaction (F (5, 54) =10.78, 
p<0.001). Post hoc comparisons of behaviours in the novel cage showed that 
naltrexone alone, or in combination with buprenorphine, significantly reduced the 
latency to drink milk in the novel cage (p <0.05, compared to saline controls). In 
addition, the novel cage was aversive as demonstrated by the significant increase in 
the latency to drink in saline treated mice in the novel cage (Mean latency value = 7.52 
± 0.86 min) compared with the home cage environment (Mean latency value = 0.53 ± 
0.18 min, p <0.001). Moreover, the SSRI fluoxetine (administered acutely 30 min 
before testing) and the -antagonist norBNI (administered at the end of training on day 
3) also significantly reduced the latency to drink in the novel cage (p <0.01, compared 
to saline).   
 
 Interestingly, buprenorphine alone significantly increased the time to drink milk 
in the home cage (p<0.001) as compared to saline and all drug treated groups. 
However, there was no significant difference between buprenorphine and saline 
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treated controls in the novel cage (p= 0.458). In a subsequent experiment (Figure 5B), 
we increased the lighting in the novel cage to enhance its aversive effects (from 300 
lux to 500 lux). We also tested the ability of the irreversible -antagonist CCAM 
(3mg/kg) to block the effects of buprenorphine and naltrexone in the NIH test (Figure 
5B, n=9 per group). In CCAM treated mice, CCAM was administered at the end of 
training on day 3. Two-way repeated measures mixed model analysis revealed 
significant main effects of Treatment (F (6, 56) =9.17 p<0.001) and an interaction 
between Treatment * Environment (F (6, 56) =26.39, p<0.001). Post hoc comparisons 
revealed that, under these conditions, buprenorphine alone significantly reduced the 
latency to drink in the novel cage (p<0.05 compared to saline control).  CCAM blocked 
the effects of buprenorphine in the home cage to increase the latency to drink 
(p<0.001) indicating that this effect was mediated by the µ-receptor. In both the home 
and novel cages, CCAM alone was without significant effect on the latency to drink, 
compared to saline controls. Furthermore, CCAM did not block the effects of 
buprenorphine or naltrexone in the novel cage, indicating that these effects on latency 
to drink in the novel cage are not -receptor mediated.  
 
 Analysis of behaviours in the EPM, using one-way ANOVA, revealed significant 
effects of Treatment on the time spent in  (F (4, 45) =3.32, p< 0.05) and number of entries 
into (F (4, 45) =4.42, p<0.01) the open arms (Figure 6 A,B,C, n= 10 per group). Within 
treatment comparisons to saline treated controls revealed that only the 
benzodiazepine diazepam (2 mg/kg) significantly increased these parameters (p 
<0.05). Neither buprenorphine nor naltrexone, alone or in combination, significantly 
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affected behaviours in the EPM. Total ambulation in the EPM was not affected by drug 
treatment (F(4, 45) =0.95 p=0.441) showing an absence of any locomotor effects.  
 
Similarly, in a separate group of mice, in the LDB there were no significant effects of 
treatment with buprenorphine and naltrexone, alone or in combination (Figure 6 D,E,F, 
n= 18 per group). One-way ANOVA revealed significant main effects of Treatment on 
the time spent in the light (F (4, 85) =3.02, p< 0.05) and dark (F (4, 85) =2.81, p< 0.05) 
compartment. Within treatment comparisons to saline controls showed that only 
diazepam (2mg/kg) significantly increased the total time spent in the light compartment 
(p<0.05). As with the EPM, total ambulation in the LDB was not significantly affected 
by drug treatment (F (4, 85) = 2.0, p= 0.102) confirming that locomotor effects were not 
a confound in these experiments.  
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DISCUSSION 
 Here, we have shown for the first time that systemic co-administration of 
buprenorphine (1mg/kg) with naltrexone (1mg/kg) in CD-1 mice produced an 
antidepressant-like response in behaviours in both the forced swim test and novelty 
induced hypophagia task, suggesting that this drug combination has potential as an 
antidepressant. Interestingly, the combination of buprenorphine with naltrexone was 
without significant effect on anxiety-related behaviours in the EPM and LDB. We have 
established that this combination dose of buprenorphine (1mg/kg) with naltrexone 
(1mg/kg) functions as a short-acting -antagonist in the tail withdrawal test. 
Furthermore, this dose combination is neither rewarding nor aversive in the CPP 
paradigm and is without significant locomotor effects.  
 
 The antidepressant potential of buprenorphine and naltrexone arises from 
studies of this combination as a treatment for opioid dependence (Gerra et al., 2006; 
Rothman et al., 2000). Naltrexone is well established as a treatment for opioid and 
alcohol dependence but patient compliance is low. Possible reasons for low 
adherence include the aversive side effects of naltrexone treatment and the fact that 
naltrexone has little effect on anhedonia symptoms associated with opioid withdrawal 
(Bouza et al., 2004; Gerra et al., 2006). The combination of naltrexone (50 mg oral 
dose) plus buprenorphine (4mg sublingual) improves mood and reduces the intensity 
of dysphoria, leading to improved retention of addicts in treatment (Gerra et al., 2006; 
Rothman et al., 2000). These authors have suggested that this drug combination 
produces -antagonism which improves mood states. Our data with the irreversible -
antagonist CCAM supports this idea. In both the forced swim test and novelty-induced 
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hypophagia task, blockade of -receptors did not affect the antidepressant-like 
response produced by treatment with combination buprenorphine/naltrexone 
indicating that these effects are mediated via -opioid receptors, rather than -
receptors.  
 
 Buprenorphine, a partial -receptor agonist and a -antagonist, has itself 
previously been shown to have antidepressant effects in depressed patients (Emrich 
et al., 1982) and in treatment resistant depressed patients (Bodkin et al., 1995; Karp 
et al., 2014). A number of preclinical trials have also demonstrated antidepressant 
effects of -receptor agonist activation. Endogenous enkephalins and endorphins 
reduced immobility and increased activity of swimming in rats (Kastin et al., 1978). In 
the mouse tail suspension test endomorphins (Fichna et al., 2007), morphine, codeine 
and other agonists reduced the time spent immobile (Berrocoso et al., 2013). More 
recently, low doses of buprenorphine (0.25 mg/kg and 0.5 mg/kg) have been shown 
to have antidepressant-like effects in the NIH and FST in C57BL/6 J mice (Falcon et 
al., 2014).  
 
However, buprenorphine’s partial -agonist activity carries a risk of abuse liability. 
While buprenorphine is not usually preferred as a primary drug of abuse, the non-
therapeutic use of buprenorphine has recently been reported to be rising among 
drug users as it serves as a substitute for other drugs of abuse (Cicero et al., 2014). 
The abuse potential would make buprenorphine alone, a less attractive 
antidepressant therapy. However, combining buprenorphine with an opioid 
antagonist would reduce the abuse liability. This is the approach that Alkermes have 
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taken in a recent placebo controlled study of the effects of buprenorphine in 
combination with a potent -opioid antagonist samidorphan (Ehrich et al., 2015) 
Following the calibration of samidorphan’s ability to block buprenorphine-induced 
effects (e.g. dose-dependent reductions in post-administration miosis) in opioid-
experienced adults, the study evaluated the effects of buprenorphine (2,4 and 8 mg), 
in 8:1 and 1:1 dose ratios with samidorphan, as adjunctive therapies in a small 
cohort of adult subjects with major depressive disorder. Patients had a current 
episode of depression and experienced inadequate response to antidepressant 
treatment. After 7 days of once daily buprenorphine/samidorphan, at a 1:1 ratio, 
depressed patients exhibited a statistically significant improvement in HAM-D17 total 
score versus placebo, with an effect size of 1.49 (Ehrich et al., 2015). While this is a 
short duration study in a small cohort of patients, it does demonstrate that the 
approach of combining buprenorphine with an opioid antagonist has clinical 
therapeutic potential. 
 
Naltrexone is often reported to have aversive effects. However, we have 
shown that naltrexone administered alone produces a significant antidepressant-like 
effect in the forced swim test and novelty induced hypophagia paradigm. Naltrexone 
is a relatively non-selective opioid receptor antagonist, with a higher affinity for - 
rather than -receptors (Giordano et al., 1990). Hence, we anticipated that 
naltrexone would reduce buprenorphine’s activation of -receptors while potentially 
enhancing its -receptor antagonist actions. We have previously shown that mixed 
-receptor antagonists produce both antidepressant and anxiolytic effects in CD-1 
mice (Casal-Dominguez et al., 2013). In overweight healthy volunteers, a daily 200 
mg dose of naltrexone was found to have no effect on mood symptoms over a 10 
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week period (Malcolm et al., 1987). However, in opioid dependent patients, with a 
high baseline affective burden, depot naltrexone treatment produced a significant 
improvement in depression scores (Mysels et al., 2011). Perhaps there is therapeutic 
potential for exploiting the mixed, relatively non-selective opioid receptor antagonists 
as antidepressant treatments, especially in patients with comorbid substance misuse 
and mood disorders (Pettinati et al., 2013). 
 
One important caveat with these findings is that they are based on mouse 
behavioural paradigms. The forced swim test is not a model of depression but is a 
well-validated and well-established behavioural task for assessing acute 
antidepressant efficacy (Cryan et al., 2002; Petit-Demouliere et al., 2005). 
Interestingly, in the forced swim test, antidepressants that target the serotonergic 
system increase swimming behaviour, whereas those that target noradrenergic 
systems increase climbing behaviour, thereby decreasing immobility (Detke et al., 
1995). In our experiments, buprenorphine and naltrexone treatment decreased 
immobility with a concomitant increase in swimming behaviour, without an effect on 
climbing behaviour. This may indicate that serotonergic pathways are implicated in the 
opioid mediated antidepressant effects seen here, as has been suggested by others 
(Bruchas et al., 2011). However, it has been argued that the forced swim test has 
limited predictive validity and that behavioural paradigms responding to chronic 
antidepressant treatments have greater validity (Mitchell and Redfern, 2005).  The 
novelty-induced hypophagia task is a procedure that has been developed to assess 
anxiety-related behaviours but has been shown to be sensitive to the chronic anxiolytic 
effects of antidepressants in rodents (Dulawa and Hen, 2005). In our study, the 
combination of buprenorphine and naltrexone has been shown to have 
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antidepressant-like effects in both the forced swim test and the novelty-induced 
hypophagia test in adult male CD-1 mice. Further studies are required to assess 
whether buprenorphine/naltrexone has any utility in animal models of depressive 
symptoms such as the Flinders Sensitive Line rat or the chronic unpredictable mild 
stress model (Neumann et al., 2011; Papp et al., 1991). 
 
Anxiety-related behaviours have been reported to be regulated by the 
dynorphin--receptor system. For example, dynorphin induced significant anxiogenic-
like effects in mice in the LDB and EPM (Narita et al., 2005), while -antagonists 
produced acute and persistent anxiolytic-like effects (Knoll et al., 2007). Interestingly, 
buprenorphine, over a similar dose range used here (0.3, 1 and 3 mg/kg) has been 
reported to show anxiogenic effects in NMRI mice in the LDB test (Lelong-Boulouard 
et al., 2006). However, in our experiments there was no evidence of buprenorphine’s 
reported anxiogenic effects. On the contrary, in the LDB, there was an apparent trend 
for buprenorphine (and buprenorphine/naltrexone combination) to increase the time 
spent in the lit compartment, almost double in comparison with saline controls, 
although these results did not achieve statistical significance. The absence of a robust 
anxiolytic-like response in the EPM and LDB was surprising but this may be because 
the mice were not sufficiently stressed in these paradigms to activate dynorphin 
release and alter anxiety behaviours (McLaughlin et al., 2006; Shirayama et al., 2004; 
Wittmann et al., 2009). Hyponeophagia, such as in tested in the novelty induced 
hypophagia task, is an anxiety-related measure that is sensitive to the effects of a wide 
range of pharmacological manipulations including benzodiazepines and SSRIs 
(Dulawa and Hen, 2005). Both acute and repeated administration of low dose 
buprenorphine has recently been shown to reduce the latency to approach food in a 
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novelty induced hypophagia task (Falcon et al., 2014). The novelty induced 
hypophagia test is a conflict-based anxiety test where the aversive novel cage 
environment suppresses the approach to a highly palatable food. The demonstration 
of an effect of combination buprenorphine/naltrexone in the novelty induced 
hypophagia task, but not in EPM and LDB, supports the potential of -antagonists in 
stress-related tasks (Cryan and Sweeney, 2011).  
 
We have shown that the combination of buprenorphine (1mg/kg) with 
naltrexone (1mg/kg) administered intraperitoneally in CD-1 mice has antidepressant 
potential. Both drugs are licensed currently for other indications so may be attractive 
to translate to the clinic. However, naltrexone is administered orally and 
buprenorphine sublingually, so achieving the correct dose combination to achieve an 
antidepressant effect may not be trivial. Cordery et al. (2014) have suggested that 
the ideal buprenorphine: naltrexone plasma concentration ratio is around 1:5 for anti-
addiction treatment. Further, they suggested that higher doses of both 
buprenorphine and naltrexone than those used by  Rothman et al. (2000) and Gerra 
et al. (2006) for treatment of opioid dependence (buprenorphine 4 mg daily/ 
naltrexone 50 mg daily) may be even more effective clinically as the combination 
would result in greater receptor occupancies. In preclinical studies, lower doses of 
buprenorphine at 0.25 and 0.5 mg/kg have been shown to have antidepressant-like 
effects in mice (Falcon et al., 2014), in comparison to 1mg/kg used in this study 
which also produced antidepressant-like effects. Interestingly, clinically significant 
effects of buprenorphine have been observed at low doses with the titrated dose 
ranging from 0.15-1.8 mg/d or 0.2-1.6 mg/d (Bodkin et al., 1995; Karp et al., 2014). 
Naltrexone would need to be carefully titrated to avoid inducing aversive side effects 
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which deters use (Bouza et al., 2004). A further limitation of this combination 
approach is the risk of diversion of buprenorphine and its abuse liability. 
Nevertheless, these data highlight the potential of combination 
buprenorphine/naltrexone as an antidepressant treatment strategy and provides an 
alternative route to achieving a shorter-acting safe and effective antagonist.  
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Figure Legends 
Figure 1. Antinociceptive effects of buprenorphine (Bup, 1mg/kg) and U50,488 (U50, 
10 mg/kg) are blocked by naltrexone (NTX) in the mouse tail withdrawal assay. The 
time course of the experiments is shown (A,C, E). Bar charts highlight the antagonist 
effects of naltrexone (NTX) at 60 min post-administration of agonist (B, D). (A,B) 
Naltrexone (NTX) dose-dependently blocked buprenorphine-induced antinociception 
(**p< 0.01; ***p< 0.001 Bup compared to saline control; $$p< 0.01; $$$p< 0.001 Bup 
alone compared to combination Bup + NTX 1 and 3 mg/kg). (C,D) Naltrexone (NTX) 
dose-dependently blocked U50,488-induced antinociception (*p< 0.05; **p< 0.01; 
***p< 0.001 U50 compared to saline control; $$p< 0.01; $$$p< 0.001 U50 alone 
compared to combination U50 + NTX 1 and 3 mg/kg).  (E) Duration of -antagonist 
effects of naltrexone alone or naltrexone/buprenorphine combination. Significant 
blockade of U50,488 induced antinociception is evident at 1 h post-administration and 
reversed by 24 h. At 8h post-administration, the combination of 
buprenorphine/naltrexone, produced a significant potentiation of U50-488-induced 
antinociception (^^^p<0.001 compared to all other treatment groups; ### p<0.001 for 
all treatment groups compared to NTX/Bup/saline controls; && p<0.01 compared to 
NTX/Bup/saline controls and compared to NTX/Saline/U50 group.  (F) The irreversible 
µ-antagonist CCAM (3 mg/kg) administered 24 h before testing blocked the NTX/Bup 
mediated potentiation of U50,488-induced antinociception at 8h post-administration 
(*p< 0.05 compared to U50 alone). All values are mean ± SEM, n= 5 per group.   
 
Figure 2. Locomotor activity in the open field in mice treated with buprenorphine (Bup, 
1mg/kg) alone and in combination with naltrexone (NTX) (0.3, 1 and 3 mg/kg). All 
values are mean ± SEM, n= 5 per group.  
 
Figure 3. Conditioned place preference to buprenorphine (Bup, 1 mg/kg) in mice, in 
the presence and absence of naltrexone (NTX) (1 and 3 mg/kg). In a 900 s test, 
animals in all treatment groups did not show preference for either chamber during 
habituation (pre-conditioning). After 6 days of conditioning, buprenorphine significantly 
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increased the time spent in the drug-paired chamber. Values are mean ± SEM, n = 8 
per group. *p=0.05 vs pre-condition group.  
 
Figure 4. Effects of buprenorphine (1mg/kg) and naltrexone (1mg/kg), alone or in 
combination, in the mouse forced swim test. The SSRI fluoxetine (20 mg/kg) was 
administered as a positive control. (A) All compounds under test produced 
antidepressant-like effects in the forced swim test. (B) The irreversible -antagonist 
CCAM (3mg/kg), administered 24h before buprenorphine, did not block the 
antidepressant-like effects of buprenorphine in the forced swim test. Data are 
expressed as mean ± SEM (n=10 per group) of time spent swimming, climbing and 
immobile during the last 4 min of a 6 min swim test. * p< 0.05,  ** p< 0.01,  ***p< 0.001 
compared to saline.  
 
Figure 5: Effects of buprenorphine (1mg/kg) and naltrexone (1mg/kg), alone or in 
combination, in the mouse novelty-induced hypophagia task. The latency to drink milk 
in both the home and novel cage environments is shown. (A) The SSRI fluoxetine (20 
mg/kg) was administered as a positive control and the selective -antagonist norBNI 
(10 mg/kg) shown for comparison (n=10 per group). (B) The irreversible antagonist 
CCAM (3 mg/kg) blocked the effects of buprenorphine (1 mg/kg) on latency to drink in 
the home cage, but not the novel cage (n=9 per group). Data are mean ± SEM. *p< 
0.05, **p< 0.01 and ***p< 0.001 compared to saline. #p< 0.05 and ###p< 0.001 for 
novel cage comparison to home cage. ^^^p< 0.001 compared to buprenorphine alone.  
 
 
Figure 6: Effects of buprenorphine (1mg/kg) and naltrexone (1mg/kg), alone or in 
combination, in the mouse elevated plus maze (A,B,C) and light-dark box (D,E,F). The 
benzodiazepine diazepam (2 mg/kg) was included as a positive control. The time 
spent in the open arms (A), number of entries into the open arms (B) and total 
ambulation (C) in the elevated plus maze are shown (n=10 per group). The time spent 
in the light box (D), in the dark box (E) and total ambulation (F) in the light dark box 
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are shown (n=18 per group). All values are the mean ± SEM.  *p< 0.05 compared to 
saline.  
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